IMPORTANCE: The association between selective @entity750 reuptake inhibitor (SSRI) antidepressant use during pregnancy and risk of @entity120 ( @entity120 ) has been controversial since the US Food and Drug Administration issued a public health advisory in 2006. OBJECTIVE: To examine the risk of @entity120 associated with exposure to different antidepressant medication classes late in pregnancy. DESIGN AND SETTING: Cohort study nested in the 2000-2010 Medicaid Analytic eXtract for 46 US states and Washington, DC. Last follow-up date was December 31, 2010. @entity1 : A total of 3,789,330 pregnant @entity1 enrolled in Medicaid from 2 months or fewer after the date of last menstrual period through at least 1 month after delivery. The source cohort was restricted to @entity1 with a @entity308 diagnosis and logistic regression analysis with propensity score adjustment applied to control for potential confounders. EXPOSURES FOR OBSERVATIONAL STUDIES: SSRI and non-SSRI monotherapy use during the 90 days before delivery vs no use. MAIN OUTCOMES AND MEASURES: Recorded diagnosis of @entity120 during the first 30 days after delivery. RESULTS: A total of 128,950 @entity1 (3.4%) filled at least 1 prescription for antidepressants late in pregnancy: 102,179 (2.7%) used an SSRI and 26,771 (0.7%) a non-SSRI. Overall, 7630 @entity1 not exposed to antidepressants were diagnosed with @entity120 (20.8; 95% CI, 20.4-21.3 per 10,000 births) compared with 322 @entity1 exposed to SSRIs (31.5; 95% CI, 28.3-35.2 per 10,000 births), and 78 @entity1 exposed to non-SSRIs (29.1; 95% CI, 23.3-36.4 per 10,000 births). Associations between antidepressant use and @entity120 were attenuated with increasing levels of confounding adjustment. For SSRIs, odds ratios were 1.51 (95% CI, 1.35-1.69) unadjusted and 1.10 (95% CI, 0.94-1.29) after restricting to @entity1 with @entity308 and adjusting for the high-dimensional propensity score. For non-SSRIs, the odds ratios were 1.40 (95% CI, 1.12-1.75) and 1.02 (95% CI, 0.77-1.35), respectively. Upon restriction of the outcome to primary @entity120 , the adjusted odds ratio for SSRIs was 1.28 (95% CI, 1.01-1.64) and for non-SSRIs 1.14 (95% CI, 0.74-1.74). CONCLUSIONS AND RELEVANCE: Evidence from this large study of publicly insured pregnant @entity1 may be consistent with a potential increased risk of @entity120 associated with maternal use of SSRIs in late pregnancy. However, the absolute risk was small, and the risk increase appears more modest than suggested in previous studies.

Antidepressant use late in pregnancy and risk of XXXX .

@entity1 :: ('9606', 'Species') :: ['women', 'infants', 'PARTICIPANTS'] @entity308 :: ('MESH:D003866', 'Disease') :: ['depression'] @entity120 :: ('MESH:D006976', 'Disease') :: ['persistent pulmonary hypertension of the newborn', 'PPHN'] @entity750 :: ('MESH:D012701', 'Chemical') :: ['serotonin']
@entity120 :: (MESH:D006976,Disease) :: ['persistent pulmonary hypertension of the newborn']
